126 related articles for article (PubMed ID: 25390056)
1. HAART and liver: is it safe?
Antonello VS; Kliemann DA; Rigel Santos B; Tovo CV
J Infect Dev Ctries; 2014 Nov; 8(11):1444-50. PubMed ID: 25390056
[TBL] [Abstract][Full Text] [Related]
2. Influence of liver fibrosis on highly active antiretroviral therapy-associated hepatotoxicity in patients with HIV and hepatitis C virus coinfection.
Aranzabal L; Casado JL; Moya J; Quereda C; Diz S; Moreno A; Moreno L; Antela A; Perez-Elias MJ; Dronda F; Marín A; Hernandez-Ranz F; Moreno A; Moreno S
Clin Infect Dis; 2005 Feb; 40(4):588-93. PubMed ID: 15712082
[TBL] [Abstract][Full Text] [Related]
3. Hepatotoxicity of antiretroviral drugs is reduced after successful treatment of chronic hepatitis C in HIV-infected patients.
Labarga P; Soriano V; Vispo ME; Pinilla J; Martin-Carbonero L; Castellares C; Casado R; Maida I; Garcia-Gasco P; Barreiro P
J Infect Dis; 2007 Sep; 196(5):670-6. PubMed ID: 17674307
[TBL] [Abstract][Full Text] [Related]
4. Hepatotoxicity of antiretroviral drugs in HIV HCV patients with congenital coagulopathies followed at an Haemophilia Unit during a decade.
Sauleda S; Martorell M; Esteban JI; Tural C; Ruiz I; Puig L; Esteban R; Guardia J; Vargas V
Haemophilia; 2006 May; 12(3):228-36. PubMed ID: 16643206
[TBL] [Abstract][Full Text] [Related]
5. [Evaluation of APRI score in liver disease following the introduction of antiretroviral therapy in HIV and HCV coinfected versus HIV monoinfected patients].
Antonello VS; Tovo CV; Kliemann DA; Santos BR; Zaltron VF
Rev Soc Bras Med Trop; 2010; 43(6):678-81. PubMed ID: 21181022
[TBL] [Abstract][Full Text] [Related]
6. Antiretroviral therapy based on protease inhibitors as a protective factor against liver fibrosis progression in patients with chronic hepatitis C.
Macías J; Mira JA; López-Cortés LF; Santos I; Girón-González JA; González-Serrano M; Merino D; Hernández-Quero J; Rivero A; Merchante N; Trastoy M; Carrillo-Gómez R; Arizcorreta-Yarza A; Gómez-Mateos J; Pineda JA
Antivir Ther; 2006; 11(7):839-46. PubMed ID: 17302246
[TBL] [Abstract][Full Text] [Related]
7. Severe transaminitis after interferon-ribavirin therapy in HIV/HCV-coinfected patients: influence of a sustained HCV response.
Bani-Sadr F; Krastinova E; Fromentin D; Piroth L; Rosenthal E; Quertainmont Y; Perronne C; Cacoub P; Pol S; Carrat F;
J Viral Hepat; 2012 Jun; 19(6):431-5. PubMed ID: 22571905
[TBL] [Abstract][Full Text] [Related]
8. Hepatotoxicity of antiretrovirals: incidence, mechanisms and management.
Núñez M
J Hepatol; 2006; 44(1 Suppl):S132-9. PubMed ID: 16364487
[TBL] [Abstract][Full Text] [Related]
9. Advanced liver fibrosis in HIV/HCV-coinfected patients on antiretroviral therapy.
Fuster D; Planas R; Muga R; Ballesteros AL; Santos J; Tor J; Sirera G; Guardiola H; Salas A; Cabré E; Ojanguren I; Barluenga E; Rey-Joly C; Clotet B; Tural C
AIDS Res Hum Retroviruses; 2004 Dec; 20(12):1293-7. PubMed ID: 15650421
[TBL] [Abstract][Full Text] [Related]
10. Incidence of and risk factors for severe hepatotoxicity of nelfinavir-containing regimens among HIV-infected patients with chronic hepatitis C.
Mira JA; Macías J; Girón-González JA; Merino D; González-Serrano M; Jiménez-Mejías ME; Caballero-Granado FJ; Torre-Cisneros J; Terrón A; Becker MI; Gómez-Mateos J; Arizcorreta-Yarza A; Pineda JA;
J Antimicrob Chemother; 2006 Jul; 58(1):140-6. PubMed ID: 16720565
[TBL] [Abstract][Full Text] [Related]
11. Hepatotoxicity from first line antiretroviral therapy: an experience from a resource limited setting.
Kalyesubula R; Kagimu M; Opio KC; Kiguba R; Semitala CF; Schlech WF; Katabira ET
Afr Health Sci; 2011 Mar; 11(1):16-23. PubMed ID: 21572852
[TBL] [Abstract][Full Text] [Related]
12. Liver injury and changes in hepatitis C Virus (HCV) RNA load associated with protease inhibitor-based antiretroviral therapy for treatment-naive HCV-HIV-coinfected patients: lopinavir-ritonavir versus nelfinavir.
Sherman KE; Shire NJ; Cernohous P; Rouster SD; Omachi JH; Brun S; Da Silva B
Clin Infect Dis; 2005 Oct; 41(8):1186-95. PubMed ID: 16163639
[TBL] [Abstract][Full Text] [Related]
13. The prevalence and risk of hepatitis flares in a Serbian cohort of HIV and HCV co-infected patients treated with HAART.
Jevtović Dj; Ranin J; Salemović D; Pesić I; Dragović G; Zerjav S; Djurković-Djaković O
Biomed Pharmacother; 2008 Jan; 62(1):21-5. PubMed ID: 17223307
[TBL] [Abstract][Full Text] [Related]
14. Association of increased hepatitis C virus (HCV)-specific IgG and soluble CD26 dipeptidyl peptidase IV enzyme activity with hepatotoxicity after highly active antiretroviral therapy in human immunodeficiency virus-HCV-coinfected patients.
Stone SF; Lee S; Keane NM; Price P; French MA
J Infect Dis; 2002 Nov; 186(10):1498-502. PubMed ID: 12404169
[TBL] [Abstract][Full Text] [Related]
15. Liver fibrosis on account of chronic hepatitis C is more severe in HIV-positive than HIV-negative patients despite antiretroviral therapy.
de Lédinghen V; Barreiro P; Foucher J; Labarga P; Castéra L; Vispo ME; Bernard PH; Martin-Carbonero L; Neau D; García-Gascó P; Merrouche W; Soriano V
J Viral Hepat; 2008 Jun; 15(6):427-33. PubMed ID: 18221303
[TBL] [Abstract][Full Text] [Related]
16. Levels of serum markers of liver inflammation and fibrosis in patients with chronic hepatitis C virus infection according to HIV status and antiretroviral use.
Connoy A; Turner J; Núñez M
AIDS Res Hum Retroviruses; 2011 Jul; 27(7):719-25. PubMed ID: 21128862
[TBL] [Abstract][Full Text] [Related]
17. Short communication: risk of elevated total cholesterol/high-density lipoprotein cholesterol ratio after antiretroviral therapy in HIV/hepatitis C virus patients.
Kakinami L; Adams MJ; Block RC; Cohn SE; Maliakkal B; Fisher SG
AIDS Res Hum Retroviruses; 2012 Dec; 28(12):1552-6. PubMed ID: 22380598
[TBL] [Abstract][Full Text] [Related]
18. Incidence of and risk factors for severe hepatotoxicity associated with antiretroviral combination therapy.
Wit FW; Weverling GJ; Weel J; Jurriaans S; Lange JM
J Infect Dis; 2002 Jul; 186(1):23-31. PubMed ID: 12089658
[TBL] [Abstract][Full Text] [Related]
19. Effect of antiretroviral therapy on liver-related mortality in patients with HIV and hepatitis C virus coinfection.
Qurishi N; Kreuzberg C; Lüchters G; Effenberger W; Kupfer B; Sauerbruch T; Rockstroh JK; Spengler U
Lancet; 2003 Nov; 362(9397):1708-13. PubMed ID: 14643119
[TBL] [Abstract][Full Text] [Related]
20. Is the increased risk of liver enzyme elevation in patients co-infected with HIV and hepatitis virus greater in those taking antiretroviral therapy?
Cicconi P; Cozzi-Lepri A; Phillips A; Puoti M; Antonucci G; Manconi PE; Tositti G; Colangeli V; Lichtner M; Monforte Ad;
AIDS; 2007 Mar; 21(5):599-606. PubMed ID: 17314522
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
